OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases $11,791.52 in Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Patrick W. Smith acquired 5,669 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average cost of $2.08 per share, for a total transaction of $11,791.52. Following the purchase, the insider now owns 1,779,572 shares of the company’s stock, valued at $3,701,509.76. This represents a 0.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

OncoCyte Trading Down 4.5 %

Shares of OncoCyte stock opened at $2.10 on Friday. The company has a 50-day simple moving average of $2.41 and a two-hundred day simple moving average of $2.85. OncoCyte Co. has a one year low of $1.97 and a one year high of $3.57.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The business had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same quarter in the prior year, the company earned ($0.57) earnings per share. As a group, sell-side analysts anticipate that OncoCyte Co. will post -2.57 earnings per share for the current year.

Hedge Funds Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC lifted its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 55.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th. StockNews.com started coverage on shares of OncoCyte in a research note on Monday. They issued a “sell” rating for the company.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.